Results 11 to 20 of about 177,775 (151)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

open access: yesFrontiers in Oncology, 2022
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie   +4 more
doaj   +1 more source

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

open access: yesFrontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitors [PDF]

open access: yesJAMA Oncology, 2015
Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire   +3 more sources

Immune checkpoint inhibitors in malignancy [PDF]

open access: yesAustralian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Immune Checkpoint Inhibitors and Neurotoxicity

open access: yesCurrent Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with varying incidence and symptom complexity ...
Zhao, Zhiyi   +4 more
openaire   +3 more sources

Research Advances in Intracranial Radiotherapy Combined with Immune Checkpoint Inhibitors on Lung Cancer Brain Metastasis

open access: yesZhongliu Fangzhi Yanjiu, 2020
In recent years, immunotherapy has been continuously developed, and the safety and efficacy of immune checkpoint inhibitors combined with intracranial radiotherapy for melanoma brain metastasis have been initially recognized.
HE Qian, REN Qinglan
doaj   +1 more source

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis

open access: yesBrazilian Journal of Oncology, 2022
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Maria Paula Furtado Santos   +9 more
doaj   +1 more source

Immune Checkpoint Inhibitor Toxicities [PDF]

open access: yesMayo Clinic Proceedings, 2019
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been
Julian A. Marin-Acevedo   +2 more
openaire   +2 more sources

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh   +4 more
doaj   +1 more source

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

open access: yesJEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy